Updates are available Correction dated 2025-07-22
Click to view Correction: https://doi.org/10.1038/s41586-025-09406-z
-
Authors
Sonke, Gabe S. https://orcid.org/0000-0001-8088-9628
van Ommen-Nijhof, Annemiek https://orcid.org/0000-0002-1797-1060
Wortelboer, Noor https://orcid.org/0009-0006-1649-748X
van der Noort, Vincent
Swinkels, Astrid C. P. https://orcid.org/0000-0002-0047-0948
Blommestein, Hedwig M. https://orcid.org/0000-0002-5846-0531
Guerrero Paez, Cristina
Mol, Linda
Beeker, Aart
Beelen, Karin
Hamming, Lisanne C.
Heijns, Joan B.
Honkoop, Aafke H. https://orcid.org/0000-0002-8066-2164
de Jong, Paul C.
van Rossum-Schornagel, Quirine C.
van Schaik-van de Mheen, Christa
Tol, Jolien
Tromp-van Driel, Cathrien S.
Vrijaldenhoven, Suzan
van Leeuwen-Stok, A. Elise https://orcid.org/0000-0003-1988-4099
Konings, Inge R.
Jager, Agnes https://orcid.org/0000-0002-7713-1450
,
de Jong, Paul C.
van Rossum-Schornagel, Quirine C.
van Schaik-van de Mheen, Christa
- License Information
-
More Information
Article History
Received: 9 January 2024
Accepted: 10 September 2024
First Online: 27 November 2024
Change Date: 22 July 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-025-09406-z
Competing interests
: G.S.S. reports institutional research support from Agendia, AstraZeneca, Merck, Novartis, Roche and Seagen; and consultancy for Biovica, Novartis and Seagen. H.M.B. received grants from CADTH, ZIN and Medical Delta; and participated in a data safety monitoring board or advisory board for Pfizer. A.H.H. received consulting fees from Gilead and Lilly; and received payment or honoraria from Lilly. Q.C.v.R.-S. has participated in a data safety monitoring board or advisory board for Roche. I.R.K. reports institutional research grant support from Novartis and Gilead. The other authors declare no competing interests.
